03/09/20 09:58 am HOUSE RESEARCH RC/JG H3223A1

1.1	moves to amend H.F. No. 3223 as follows:
1.2	Page 2, after line 9, insert:
1.3	"(d) This section does not apply to coverage provided through a public health care
1.4	program under chapter 256B or 256L, or health plan coverage through the State Employee
1.5	Group Insurance Plan (SEGIP) under chapter 43A.
1.6	EFFECTIVE DATE. This section is effective January 1, 2021."
1.7	Page 2, after lines 22 and 29, insert:
1.8	"EFFECTIVE DATE. This section is effective January 1, 2021."
1.9	Page 3, delete sections 4 and 5 and insert:
1.10	"Sec. 4. STUDY OF PHARMACY AND PROVIDER CHOICE OF BIOLOGICAL
1.10 1.11	"Sec. 4. STUDY OF PHARMACY AND PROVIDER CHOICE OF BIOLOGICAL PRODUCTS.
1.11	PRODUCTS.
1.11	PRODUCTS. The commissioner of health, within the limits of existing resources, shall analyze the
1.11 1.12 1.13	PRODUCTS. The commissioner of health, within the limits of existing resources, shall analyze the effect of Minnesota Statutes, section 62W.0751, on the net price for different payors of
1.11 1.12 1.13 1.14	PRODUCTS. The commissioner of health, within the limits of existing resources, shall analyze the effect of Minnesota Statutes, section 62W.0751, on the net price for different payors of biological products, interchangeable biological products, and biosimilar products. The
1.11 1.12 1.13 1.14 1.15	PRODUCTS. The commissioner of health, within the limits of existing resources, shall analyze the effect of Minnesota Statutes, section 62W.0751, on the net price for different payors of biological products, interchangeable biological products, and biosimilar products. The commissioner of health shall report findings to the chairs and ranking minority members

Sec. 4.